Comparison of Levofloxacin Versus Clarithromycin Based Triple Therapy in the Eradication of H. Pylori Infection in Patients Visiting Tertiary Care Hospital in Peshawar
Abstract
Background: Helicobacter pylori infection is a major cause of chronic gastritis, peptic ulcer disease, and gastric malignancy worldwide. The effectiveness of standard clarithromycin-based triple therapy has declined over recent years due to increasing antibiotic resistance, particularly in developing countries. Levofloxacin-based triple therapy has emerged as a potential alternative with improved eradication rates.
Objective: To compare the efficacy, safety, and compliance of levofloxacin-based versus clarithromycin-based triple therapy in eradication of H. pylori infection among patients attending a tertiary care hospital in Peshawar.
Methods: This comparative cross sectional study was conducted on 240 H. pylori-infected patients. Patients were divided into two equal groups receiving either levofloxacin-based or clarithromycin-based triple therapy for 14 days. Assessment of eradication was conducted 4-6 weeks after treatment was administered in terms of urea breath test or stool antigen test.
Results: The eradication rate was much more in levofloxacin group (85.8%) than in clarithromycin group (71.7%) (p = 0.004). Side effects were mild in both groups and metallic taste disturbance was significantly more common in clarithromycin group. In both groups the compliance was high.
Conclusion: Levofloxacin-based triple therapy provided higher eradication rates and comparable safety and compliance, showing it may be a more suitable first-line treatment option in regions with high…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.